Search for Clinical Trial Results

Sponsored By

Cryopyrin-Associated Periodic Syndromes - 19 Studies Found

Status Study
Completed Study Name: The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
Condition: Cryopyrin Associated Periodic Syndrome
Date: 2010-03-25
Interventions: Drug: canakinumab (company code: ACZ885D)
Terminated Study Name: HL2351 CAPS Phase II Study
Condition: Cryopyrin‑Associated Periodic Syndromes (CAPS)
Date: 2016-05-10
Interventions: Drug: HL2351 The dose will be adjusted based on disease activities
Recruiting Study Name: Kineret CAPS Post Authorisation Study
Condition: Cryopyrin-Associated Periodic Syndromes
Date: 2014-12-01
Interventions: Drug: anakinra (Kineret) Other Name: Kineret
Completed Study Name: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Condition:
  • Cryopyrin-associated Periodic Syndromes
  • Familial Cold Autoinfla
    Date: 2011-02-22
    Interventions: Drug: ACZ885
Completed Study Name: Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
Condition:
  • Cryopyrin-associated Periodic Syndromes
  • Familial Cold Autoinfla
    Date: 2009-10-06
    Interventions: Drug: canakinumab canakinumab
Completed Study Name: Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Condition:
  • Cryopyrin-Associated Periodic Syndromes
  • Familial Cold Autoinfla
    Date: 2008-05-27
    Interventions: Drug: Canakinumab (ACZ885) 6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with
Completed Study Name: Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Condition:
  • Familial Cold Autoinflammatory Syndrome (FCAS)
  • Familial Cold Urticaria
  • Drug: rilonacept 160 mg Rilona
Completed Study Name: Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
Condition:
  • Cryopyrin-associated Periodic Syndromes (CAPS)
  • Familial Cold Au
    Date: 2010-09-30
Completed Study Name: Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)
Condition:
  • Muckle-Wells Syndrome
  • Schnitzler Syndrome

Date: 2010-01-07
Interventions: Drug: rilonacept 160mg of rilonacept 1x/week Other N
Recruiting Study Name: Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)
Condition:
  • NOMID
  • CAPS
  • DIRA
  • NLRC4-MA
    Date: 2016-11-23
Next >>>